MorphoSys Competitors

MorphoSys (NASDAQ:MOR) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares MorphoSys and Zai Lab's gross revenue, earnings per share and valuation.

MorphoSys has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 81.3% of Zai Lab shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MorphoSys and Zai Lab, as provided by MarketBeat.com.

Zai Lab has a consensus target price of $159.00, indicating a potential upside of 17.04%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts plainly believe Zai Lab is more favorable than MorphoSys.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares MorphoSys and Zai Lab's net margins, return on equity and return on assets.

Summary

MorphoSys beats Zai Lab on 8 of the 13 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares MorphoSys and Teva Pharmaceutical Industries' gross revenue, earnings per share and valuation.

MorphoSys has higher earnings, but lower revenue than Teva Pharmaceutical Industries. MorphoSys is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MorphoSys and Teva Pharmaceutical Industries, as provided by MarketBeat.com.

Teva Pharmaceutical Industries has a consensus target price of $11.6364, indicating a potential upside of 10.19%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than MorphoSys.

Insider and Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares MorphoSys and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Summary

Teva Pharmaceutical Industries beats MorphoSys on 9 of the 14 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares MorphoSys and Bausch Health Companies' gross revenue, earnings per share and valuation.

MorphoSys has higher earnings, but lower revenue than Bausch Health Companies. MorphoSys is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for MorphoSys and Bausch Health Companies, as provided by MarketBeat.

Bausch Health Companies has a consensus target price of $31.50, indicating a potential downside of 2.17%. Given Bausch Health Companies' stronger consensus rating and higher possible upside, analysts clearly believe Bausch Health Companies is more favorable than MorphoSys.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares MorphoSys and Bausch Health Companies' net margins, return on equity and return on assets.

Summary

Bausch Health Companies beats MorphoSys on 10 of the 14 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares MorphoSys and Grifols' gross revenue, earnings per share and valuation.

Grifols has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for MorphoSys and Grifols, as provided by MarketBeat.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 15.2% of Grifols shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares MorphoSys and Grifols' net margins, return on equity and return on assets.

Summary

Grifols beats MorphoSys on 7 of the 10 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares MorphoSys and Dr. Reddy's Laboratories' gross revenue, earnings per share and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for MorphoSys and Dr. Reddy's Laboratories, as provided by MarketBeat.

Dr. Reddy's Laboratories has a consensus target price of $70.00, indicating a potential upside of 13.34%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than MorphoSys.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares MorphoSys and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Summary

Dr. Reddy's Laboratories beats MorphoSys on 10 of the 14 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares MorphoSys and Mirati Therapeutics' gross revenue, earnings per share and valuation.

MorphoSys has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for MorphoSys and Mirati Therapeutics, as provided by MarketBeat.

Mirati Therapeutics has a consensus target price of $218.5714, indicating a potential upside of 19.78%. Given Mirati Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mirati Therapeutics is more favorable than MorphoSys.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are held by institutional investors. 4.1% of Mirati Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares MorphoSys and Mirati Therapeutics' net margins, return on equity and return on assets.